Hong-My Nguyen
Immunotherapeutics & Biotechnology
 |
|
Biography
Hong-My Nguyen completed her Bachelor of Pharmacy (BPharm) degree from The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India in 2015, and then worked 2015-2019 as a Medical Science Liaison for AstraZeneca in Vietnam. She joined the Graduate Program in Pharmaceutical Sciences as a Doctor of Philosophy (PhD) student in August of 2019, and is presently working in the laboratory of Dr. Laurence Wood with the Department of Immunotherapeutics and Biotechnology in Abilene.
Education:
- BPharm: The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India, 2015
Research Interests:
My primary research interest encompasses the areas of cancer immunotherapy, with a focus on oncolytic viruses and their application as monotherapy or in combination with immunotherapies, in triple-negative breast cancer (TNBC).
Publications:
- Oladejo M, Nguyen HM, Seah H, Datta A, Wood LM. Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma. Cancer Immunol Immunother. 2023 Jun; 72(6):1633-1646. Epub 2022 Dec 31.
- Nguyen HM, Gaikwad S, Oladejo M, Agrawal MY, Srivastava SK, Wood LM. Interferon stimulated gene 15 (ISG15) in cancer: An update. Cancer Lett. 2023 Mar 1; 556:216080. Epub 2023 Feb 1.
- Nguyen HM, Gaikwad S, Oladejo M, Paulishak W, Wood LM. Targeting Ubiquitin-like Protein, ISG15, as a Novel Tumor Associated Antigen in Colorectal Cancer. Cancers (Basel). 2023 Feb 15; 15(4):1237.
- Nguyen HM, Paulishak W, Oladejo M, Wood L. Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. Breast Cancer. 2022 Nov 18. Epub ahead of print.
- Oladejo M, Nguyen HM, Silwal A, Reese B, Paulishak W, Markiewski MM, Wood LM. Listeria-based immunotherapy directed against CD105 exerts antiangiogenic and anti-tumor efficacy in renal cell carcinoma. Front Immunol. 2022 Nov 11; 13:1038807.
- Nguyen HM, Bommareddy PK, Silk AW, Saha D. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Semin Cancer Biol. 2022 Nov; 86(Pt 3):971-980. Epub 2021 May 24.
- Nguyen HM, Sah N, Humphrey MRM, Rabkin SD, Saha D. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus. J Vis Exp. 2021 May 13;(171).
- Nguyen HM, Saha D. The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment. Oncolytic Virother. 2021 Feb 24; 10:1-27.
- Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. Pathogenetic Features and Current Management of Glioblastoma. Cancers (Basel). 2021 Feb 18; 13(4):856.
- *Ghouse SM, *Nguyen HM, Bommareddy PK, Guz-Montgomery K, Saha D. Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis. Front Oncol. 2020 Mar 24;10:384. [* co-first authors]
- Nguyen HM, Guz-Montgomery K, Saha D. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells. 2020 Feb 10;9(2):400.
Presentations:
- Hong-My Nguyen, Laurence M Wood. "Bugs as drugs: a promising immunotherapeutic approach for solid tumors". Pfizer Pharmaceutical Careers and Postdoctoral Opportunities Educational Event, Pfizer Worldwide Research, Development and Medical (WRDM) Postdoc Program, Cambridge, MA; November 2022.
- Hong-My Nguyen, Laurence Wood. "Listeria-based vaccines targeting interferon-stimulated gene 15 (ISG15) for renal cell carcinoma and colorectal cancer". American Society for Radiation Oncology (ASTRO) Annual Meeting, San Antonio, TX; October 2022.
- "Rapid Fire" Oral Presentation: Hong-My Nguyen and Laurence Wood. "A Listeria-Based Vaccine Targeting Interferon-Stimulated Gene 15 for Renal Cell Carcinoma". American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, Boston, MA; October 2022.
- Hong-My Nguyen and Laurence M. Wood. "Listeria-based vaccine targeting interferon-stimulated gene 15 for renal cell carcinoma". Society for Immunotherapy of Cancer (SITC) 2022 Tumor Immune Microenvironment: A Holistic Approach, San Diego, CA; April 2022.
- Podium Presentation: Hong-My Nguyen, Laurence. M. Wood. "Listeria-based vaccines targeting interferon-stimulated gene 15 (ISG15) for renal cell carcinoma and colorectal cancer". Student Research Week, Ογ½ΆΦ±²₯ Graduate School of Biomedical Sciences, Lubbock; March 2022.
Seminars:
- 03/10/2023 "Bugs as Drugs: A Promising Immunotherapeutic Approach for Solid Tumors" [Dissertation Defense, presentation counted as Seminar credit]
- 12/03/2021 "Oncolytic herpes simplex virus for de novo metastatic breast cancer" [Oral Qualifying Exam, public presentation counted as Seminar credit]
- 04/09/2021 "Oncolytic Herpes Simplex Virus for Triple-Negative Breast Cancer"
Awards/Scholarships:
- Graduate Research Grant, The Honor Society of Phi Kappa Phi (International), February 2023.
- Pfizer Worldwide Research, Development, and Medical (WRDM) Postdoc Program (invited attendee, travel costs covered), Pfizer Pharmaceutical Careers and Postdoctoral Opportunities Educational Event, Cambridge, MA; November 2022.
- Conference Travel Grant, Disease Models & Mechanisms (DMM), American Society for Radiation Oncology (ASTRO) Annual Meeting, San Antonio, TX; October 2022.
- Travelship, American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, Boston, MA; October 2022.
- Honorable Mention for Grant Application, Graduate Women in Science (GWIS) National Fellowship Program, July 2022.
- Best Abstract Award, American Association of Pharmaceutical Scientists (AAPS), PharmSci 360; Boston, MA; October 2022 [rec'd June 2022].
- Student Research Week Scholarship (sponsored by Dr. Beverly Chilton), Student Research Week, Ογ½ΆΦ±²₯ Graduate School of Biomedical Sciences in Lubbock; May 2022.
- Travel Grant Award, Cayman Chemical Co., Society for Immunotherapy of Cancer (SITC) 2022 Tumor Immune Microenvironment: A Holistic Approach, San Diego, CA; April 2022.
- Phonathon Endowed Scholarship, Ογ½ΆΦ±²₯ Student Government Association (SGA), February 2022 [to be applied graduating term].
Memberships:
- Immunotherapeutics and Biotechnology (IBGSA), Ογ½ΆΦ±²₯, 2019-present.